Articles by Daniel Brooks
UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal
UCB's acquisition of Candid Therapeutics strengthens autoimmune pipeline as Two River and Vida Ventures celebrate successful exit from clinical-stage biotech.
NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment
Australia's TGA approves NIKTIMVO (axatilimab), a breakthrough first-in-class therapy for chronic graft-versus-host disease under priority review.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera Treatment
Incyte receives FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, offering improved dosing convenience for rare blood cancer patients.
SFDA expedited review oncology: What You Need to Know
Learn about the SFDA's expedited review for oncology drugs, including [Drug Name], designed to fast-track approvals and improve patient access to essential cancer therapies.
Oculis to Present DME Research and Pipeline Updates at ARVO 2026 Annual Meeting
Oculis will present findings from DME AWARE Delphi Study highlighting unmet needs in diabetic macular edema treatment at ARVO 2026 meeting.
Viatris Presents Six Studies on Low-Dose Estrogen Contraceptive Patch at ACOG 2026
Viatris showcases clinical data for investigational weekly contraceptive patch at American College of Obstetricians and Gynecologists meeting May 1-3.
The Common Fund Data Ecosystem (CFDE)
The CFDE integrates diverse NIH datasets, offering access to over 10 million files to enhance biomedical research and discovery.
AC Immune Advances ACI-24 Alzheimer's Trial to Final Cohort, Initiates ACI-19764 Phase 1 Study
AC Immune progresses ACI-24 Alzheimer's treatment to final trial phase while starting new brain-penetrant NLRP3 inhibitor study in Q1 2026 update.
Mabwell 9MW2821 Cervical Cancer Data to Be Presented at ESMO GC 2026 Conference
Mabwell announces presentation of clinical trial data for 9MW2821, a novel Nectin-4 targeting ADC for cervical cancer treatment at ESMO GC 2026.
ImmunityBio (IBRX) Faces FDA Warning Letter and Class Action Lawsuit Over Ankt Drug Promotion Violations
ImmunityBio faces securities lawsuit after FDA warning letter over promotional claims for lead biologic Ankt, impacting IBRX stock from January-March 2026.
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.
EMA Conditional Approvals CAR-T: Insights on Relapsed B-Cell Lymphomas
This article delves into the insights and implications of EMA's conditional approvals for CAR-T therapies in the management of relapsed B-cell lymphomas.
FDA Approval Elranatamab: Efficacy, Safety & Market Impact in RRMM
Elranatamab has gained FDA approval for relapsed/refractory multiple myeloma, showcasing promising efficacy and safety, and is set to impact the market significantly.
ANVISA Regulatory Changes: Impact on Foreign Pharma Expedited Approvals
Discover how recent ANVISA regulatory changes affect expedited approvals for foreign pharmaceutical companies, streamlining access to essential medications.
SFDA Expedited Drug Approval: Impact on Saudi Pharma Market 2024-2025
The SFDA's expedited drug approval is set to revolutionize the Saudi pharmaceutical market, enhancing access to critical medications like XYZ for diabetes in 2024-2025.
ANVISA Accelerated Approval: Two-Year Impact on Breakthrough Cancer Therapies
This article examines the significant effects of ANVISA's accelerated approval process on breakthrough cancer therapies, including Keytruda for melanoma and lung cancer.
Avicanna Welcomes U.S. Cannabis Rescheduling Decision, Advances Medical Cannabis R&D Strategy
Avicanna Inc. applauds U.S. medical cannabis rescheduling announcement, supporting the company's pharmaceutical strategy and clinical development initiatives.
AstraZeneca's BREZTRI Aerosphere Approved as First Triple Therapy for Asthma in Patients 12 and Older
AstraZeneca receives FDA approval for BREZTRI Aerosphere as the first and only triple-combination therapy for asthma maintenance treatment in patients aged 12+.
Tovecimig Shows 56% Reduction in Cancer Progression Risk in Biliary Tract Cancer Trial
Tovecimig bispecific antibody demonstrates statistically significant improvement in progression-free survival versus paclitaxel alone in Phase 2/3 trial.
Sagimet Biosciences Plans Phase 3 Denifanstat Trial for Acne Treatment in 2026
Sagimet Biosciences announces Phase 3 trial for denifanstat acne treatment starting H2 2026, while advancing TVB-3567 FASN inhibitor in Phase 1 studies.